🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

6,931 results for “The” Clear

  1. DYNE-251

    Dyne Therapeutics

    Duchenne Muscular Dystrophy (DMD)

    phase 2 small molecule active

    1 trial

  2. DYP688

    Novartis Pharmaceuticals

    Metastatic uveal melanoma, other GNAQ/11 mutant melanomas (e.g. skin or mucosal melanoma)

    phase 2 small molecule active

    1 trial

  3. DZR123, DZR123, ENZALUTAMIDE

    Novartis Pharmaceuticals

    advanced, solid, relapsed tumors / advanced tumors: human lymphomas / solid human tumor indications (urothelial carcinoma, or other advanced/metastatic solid tumors, ovarian clear cell cancer, endometrial carcinoma, lymphoma including peripheral T-cell Lymphoma and GCBDLBCL, malignant pleural or peritoneal mesothelioma, metastatic castration - resistant prostate cancer (mCRPC))

    phase 2 small molecule active

    1 trial

  4. Dabogratinib (TYRA-300) 60mg

    Tyra Biosciences

    Low Grade Upper Tract Urothelial Carcinoma

    phase 2 small molecule active

    1 trial

  5. Dalpiciclib

    The First People's Hospital of Lianyungang

    Early Breast Cancer

    phase 2 small molecule active

    1 trial

  6. Dapagliflozin 10mg Tab

    The University of Hong Kong

    Lupus Nephritis

    phase 2 small molecule active

    1 trial

  7. Darinaparsin

    Alaunos Therapeutics

    Hematologic Neoplasms

    phase 2 small molecule completed

    1 trial

  8. Darinaparsin

    Alaunos Therapeutics

    HEPATOCELLULAR CARCINOMA

    phase 2 small molecule active

    1 trial

  9. Darinaparson

    Alaunos Therapeutics

    Multiple Myeloma

    phase 2 small molecule active

    1 trial

  10. Darleukin, Fibromun

    Philogen S.p.A.

    Patients with high-risk, locally advanced (non-metastatic, node negative, single or multifocal), Basal Cell Carcinoma (BCC) or cutaneous Squamous Cell Carcinoma (cSCC) amenable to intratumoral injection, not eligible to surgery or radiation therapy according to the evaluation of a local interdisciplinary tumor board or who refuse surgery or radiation therapy and for whom a histological evaluation is available according to international guidelines.

    phase 2 small molecule active

    1 trial

  11. Darolutamide+ADT

    The First People's Hospital of Lianyungang

    Prostate Cancer

    phase 2 small molecule active

    1 trial

  12. Dasatinib/Teva 50 mg επικαλυμμένα με λεπτό υμένιο δισκία, Maltodextrine powder, SPRYCEL 20 mg film-coated tablets

    The George Institute

    Human immunodeficiency virus

    phase 2 small molecule active

    1 trial

  13. Datopotamab deruxtecan

    AstraZeneca AB

    Locally Advanced Inoperable or Metastatic Breast Cancer Refractory to Endocrine Therapy

    phase 2 small molecule active

    1 trial

  14. Dazucorilant 300 mg

    CORCEPT THERAPEUTICS INC

    Amyotrophic Lateral Sclerosis

    phase 2 small molecule active

    1 trial

  15. Decitabine

    The University of Hong Kong

    Acute Myeloid Leukemia

    phase 2 small molecule active

    1 trial

  16. Decitabine

    Karyopharm Therapeutics Inc

    Ovarian Cancer

    phase 2 small molecule active

    1 trial

  17. Deep-sea fish oil

    The First People's Hospital of Lianyungang

    Radiation Toxicity

    phase 2 small molecule active

    1 trial

  18. Dendritic Cell/Tumor Fusion Vaccine

    United Therapeutics Europe Ltd

    Breast Cancer

    phase 2 mab terminated

    1 trial

  19. Deramiocel (CAP-1002)

    CAPRICOR THERAPEUTICS, INC.

    Duchenne Muscular Dystrophy

    phase 2 mab active

    1 trial

  20. Dermatophagoides Farinae Drops Group 1

    The First People's Hospital of Lianyungang

    Atopic Dermatitis

    phase 2 mab completed

    1 trial

  21. Descartes 08

    Cartesian Therapeutics

    Myeloma Multiple

    phase 2 mab terminated

    1 trial

  22. Descartes-08

    Cartesian Therapeutics

    Systemic Lupus Erythematosus (SLE)

    phase 2 small molecule active

    1 trial

  23. Descartes-08

    Cartesian Therapeutics

    Myasthenia Gravis, Generalized

    phase 2 small molecule active

    1 trial

  24. Descartes-08

    Cartesian Therapeutics

    Antisynthetase Syndrome

    phase 2 small molecule active

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources